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ABSTRACT 
 
 
Objectives 
 
 
The use of software-based MR-TRUS fusion to deliver focal therapy may increase the precision of 
treatment. This is a prospective development study assessing the feasibility of MRI-TRUS fusion focal 
cryotherapy. 
 
Methods and materials 
 
 
Consecutive patients undergoing focal cryotherapy were included in an academic registry (Dec 2013- 
June 2014). MRI-TRUS fusion focal cryotherapy was offered to men with visible clinically significant 
prostate cancer (Galil SeedNet system). Eligibility was determined by multi-parametric MRI (mpMRI), 
and transperineal template mapping or targeted biopsies. A rigid fusion platform (Biojet) was used 
with the operator ensuring the ice-ball covered at least the lesion. Adverse events were scored using 
the NCICTC V4. Genito-urinary toxicity was assessed using patient-reported outcome measures (IPSS, 
IIEF-15 and UCLA-EPIC). Early contrast-enhanced MRI and mpMRI at 6-12 months were used to 
assess extent of lesion ablation. 
 
Results 
 
 
Of 23 patients scheduled, 5 did not have image-fusion due to surgeon preference. 18 undergoing 
image-fusion cryotherapy had median age 68 (IQR 65-73) years and median preoperative PSA 9.54 
(5.65-16) ng/ml. 13 (72.2%) and 5 (27.8%) patients had intermediate and high-risk cancer, 
respectively. Ten adverse events were reported with one of these as serious (grade 3) due to admission 
for haematuria requiring wash-out only. There was no difference in the IIEF-15 between baseline 
and study end (p=0.24). The IPSS remained stable (p=0.12), while the UCLA-EPIC tended to improve 
(p=0.065). The PSA significantly decreased at 1.8 (1.04-2.93) ng/ml (p<0.001). Early and late mpMRI 
showed no residual disease in the treated area. In two men, radiological progression of known 
contralateral disease was observed; both underwent focal HIFU. 
Conclusion 
 
 
MRI-TRUS fusion focal cryotherapy is feasible in most patients and seems to accurately  guide ablation 
demonstrated by post-treatment imaging. Additional studies are needed to determine efficacy using 
post-cryotherapy biopsy. 
1. Introduction 
 
 
The therapeutic ratio of current radical treatments for localised prostate cancer is being questioned 
by clinicians, authorities and lately by patients themselves. Recent randomised trials have questioned 
the exact benefit from radical treatments across all localised prostate cancer, but do point to survival 
advantages in men with clinically significant disease who have a good life expectancy [1-3]. 
Nonetheless, the genito-urinary toxicity of radical treatments can be significant with a rate of erectile 
dysfunction and urinary incontinence varying between 30-60% and 15-20%, respectively, and a high 
rate of serious complications in the long-term, especially in older patients [4, 5]. To re-balance the 
therapeutic ratio, one strategy that has been proposed is focal therapy [6]. 
This strategy aims to treat the area of the prostate harbouring the largest volume, highest grade 
(index) lesion with a margin, while preserving the rest of the gland and reducing collateral tissue 
damage [7]. Concern and enthusiasm both exist with regard to this novel approach [6, 8]. Despite the 
open debate, there is consensus that although further robust research is required, focal therapy is an 
attractive strategy for patients and health-care systems. 
 
Focal therapy can be delivered using various sources of energy. A recent systematic review of the 
literature has shown variable results with urinary incontinence, erectile dysfunction and disease 
control (using histological outcome measures) ranging between 0-5%, 0-46% and 77-96.3%, 
respectively [9]. Focal therapy efficacy has been criticised in light of two issues: first, some novel 
sources of energy have not been tested in the clinical setting; therefore, treatment failure might be 
related to incomplete ablation, rather than failure of the focal strategy. Second, the inability of 
devices to deliver precise therapy in the area harbouring the index lesion. 
In this study, we sought to assess the feasibility of focal cryotherapy delivered to the index lesion 
using software-based MRI-TRUS fusion. 
  
 
2. Materials and Methods 
 
 
2.1 Design 
 
 
Consecutive patients undergoing software-based MRI-TRUS fusion focal cryotherapy were identified 
from a prospective academic registry (Dec 2013-June 2014). Signed informed consent was obtained. 
Internal Review Board approval was waived by the local Joint Research Office. This report is adherent 
to the recommendations of the Idea Development Evaluation Assessment and Long-term (IDEAL) 
guidelines for stage I-IIa prospective development studies assessing novel technologies  in surgery[10]. 
 
2.2 Population 
 
 
In our unit, men with primary localized prostate cancer as well as men with recurrent disease after 
initial radiation or ablative therapy underwent mpMRI. Images were acquired in a 1.5 or 3T scanner 
with a pelvic coil using a standard protocol including T2-weighted, diffusion-weighted and dynamic 
contrast enhanced sequences. Every scan was reported by an experienced radiologist reporting all 
zones with a Likert score between 3 (equivocal  presence of clinically significant disease) and 5 
(extremely likely presence of clinically significant disease) [11]. Histological characterisation of the 
radiological phenotype was obtained according to the mpMRI report. Transperineal targeted biopsy 
with no additional sampling to zones scoring </=2 were performed in men with a single lesion; 
template prostate mapping biopsies were offered to men with multiple lesions or diffuse equivocal 
findings (figure 1). Treatment-naïve men with Gleason pattern >/=4 and/or PSA >/=10ng/ml as well 
as all men with radiorecurrent disease also underwent a radioisotope bone-scan to rule-out 
metastases. 
MRI-TRUS software-based fusion focal cryotherapy was offered to men with one or two MR-visible 
lesions confirmed to be clinically significant in whom a standard focal strategy was deemed to be 
able to achieve complete ablation (hemi-, quadrant, focal or bi-focal ablation). 
 
2.3 Procedure 
 
 
Before the procedure, the full 3mm thickness T2-weighted sequence was downloaded and imported 
onto the Biojet rigid image-fusion platform (D&K Technologies GmbH, Barum, Germany). The 
prostate as well as visible lesion(s) were contoured [12]. The cryotherapy procedure was carried out 
in the lithotomy position. Antibiotic prophylaxis was administered  intravenously at induction of 
general anaesthesia. First, the prostate was scanned using a bi-plane transrectal ultrasound probe 
(Hitachi Preirus, Hitachi Aloka Medical America, Inc. Wallignford USA) positioned on a stepper fixed 
to the operation table by a flexible arm (D&K Technologies GmbH, Barum, Germany). Second, the 
Biojet computer was connected to the ultrasound probe via sensors located on the stepper, one for 
tracking longitudinal movements and one for rotation. MRI-TRUS fusion was obtained manually by 
aligning the contour of the prostate drawn on the MRI to the margins of the prostate visible on the 
TRUS by rigid registration. Third, cryotherapy needles were inserted transperineally via a 
brachytherapy grid in order to ensure a parallel position. The cryotherapy needles were placed using 
the Biojet platform for guidance in order to cover the area to ablate with a margin of 1cm (figure 2). 
We used the cryotherapy SeedNet® system (Galil Medical Inc. Arden Hills, MN 55122, USA) with 17 
Gauge (1.5mm) needles. Two types of needle were chosen according to the dimensions of the lesion 
to ablate on the axial and the longitudinal MR/TRUS software. IceRod needles achieve a complete 
ablation of 41mm longitudinally, whereas IceSeeds achieve 19mm. Thermocouples were then placed 
within the ablation area, and in the Denovilliers’ fascia in case of posterior or mid-gland lesions, or in 
the peripheral area in case of anterior lesions. 
Fourth, a flexible cystoscopy was performed to rule out urethral perforation, and a urethral warmer 
was inserted. Finally, two freeze-thaw cycles were delivered to achieve a temperature below minus 
40°C in the ablation area, as measured by thermocouples. A temperature above 0°C was maintained 
in the area of the posterior thermocouple. At the end of the procedure, a urethral catheter was left 
in place, and the patient was discharged the same day. 
 
2.4 Follow up 
 
 
The urethral catheter was removed at 7-10 days after the procedure, and an early contrast-enhanced 
MRI was carried between 7-21 days to evaluate ablation. Patients were reviewed in clinics at 3, 6, 9 
and 12 months with PSA measurements. Validated questionnaires were posted to patients at baseline 
and every three months following the procedure: 15-item International Index of Erectile Function 
(IIEF-15), International Prostate Symptoms Score (IPSS), and University of California Los Angeles 
Expanded Prostate Cancer Index Composite (UCLA-EPIC) urinary function [13, 14]. Non- responders 
at baseline were not sent questionnaires after treatment. Late mpMRI was carried out between 6 
to 12 months, and scored according to the likelihood of presence of significant residual disease from 
1 (extremely unlikely) to 5 (extremely likely). Complications were scored according to the Common 
Terminology Criteria for Adverse Events (CTCAE) version 4. 
 
2.5 Statistical Analysis 
 
 
Continuous variables are displayed as median and interquartile range (IQR); categorical variables as 
frequencies and percentages. Variation over time of continuous variables is represented by box and 
whisker plots. Two-tailed Wilcoxon signed rank test was employed to evaluate variation of 
continuous variables between baseline and 12 months follow-up. A p-value </= 0.05 was considered 
statistically significant. Statistical analysis was carried out using SPSS® version 20.0 (IBM corporation, 
Armonk, NY, USA). 
 
 
 
 
3. Results 
3.1 Study population 
 
 
Twenty-three patients were scheduled for MRI-TRUS fusion focal cryotherapy. Five of them were 
excluded as the registration system could not be used to plan the treatment. In three of these, the 
histological results showed the extent of the disease to be beyond the visible lesion; therefore, the 
MRI lesion alone could not be used for treatment planning. In two patients, MRI-TRUS registration 
was judged by the surgeon as lacking sufficient accuracy, and the procedure was performed using 
visual/cognitive estimation as per standard of care. Of note, both patients had recurrent disease, one 
after radiation therapy and one after focal High Intensity Focused Ultrasound (HIFU), which cause 
significant gland distortion. 
Eighteen patients constitute the cohort of this analysis. Median age was 68 (IQR 65-73) years and 
median preoperative PSA 9.54 (5.65-16) ng/ml. 14 (77.8%) had primary disease and 4 (22.2%) had 
recurrent disease (table 1)  with NCCN intermediate and high risk in  13 (72.2%) and 5 (27.8%), 
respectively. 
3.2 Perioperative outcome 
 
 
Uni-focal, bi-focal and hemi-ablation were performed in 12 (66.7%), 4 (22.2%), 2 (11.1%) patients, 
respectively. Median procedure time was 85 (74-100) minutes for an overall anaesthetic time at 120 
(108-145) minutes. Median hospitalization time was 11 (9.5-22.5) hours. Catheter removal was 
performed after a median of 8 (7-9) days (table 2). 
 
3.3 Adverse events 
 
 
10 adverse events were recorded. 1 of 11 was a serious adverse event, scoring CTCAE grade 3. This 
patient was hospitalised the day of the procedure with continuous irrigation for haematuria with 
clots. He was discharged after two days, and the catheter was successfully removed 10 days later. 
Among the 10 CTCAE grade 1 and 2 adverse events, three had urinary infections, three failed first 
trial without catheter, two had self-resolving urinary dribbling, one had a urethral stricture that 
required dilation under local anaesthetic, and one complained of temporary penile numbness. 
3.4 Functional outcome 
 
 
Thirteen (72.2%) replied to questionnaires at baseline and follow-up. In terms of erectile function, 
the IIEF-15 score decreased after three months from cryotherapy, while there was no statistically 
significant difference between baseline and last follow-up at 12 months (p=0.24) (supplementary 
figure 1). The number of patients using PDE-5 inhibitors increased from 2 (11.1%) at baseline to 5 
(27.8%). In terms of urinary function, the IPSS remained stable over time with no difference between 
baseline and 12 months (p=0.12) (supplementary figure 2); the IPSS quality-of-life score significantly 
improved (p=0.026) (supplementary figure 3). The UCLA-EPIC urinary domain tended to improve but 
this did not reach statistical significance (p=0.065) (supplementary figure 4). 
 
3.5 Ablation effect 
 
 
The PSA significantly decreased  from baseline to  12 months  follow-up  at 1.8 (1.04-2.93) ng/ml 
(p<0.001) (supplementary figure 5). Early MRI scan showed score 1 (highly unlikely), 2 (unlikely) and 
4 (likely) with respect to presence of clinically significant residual disease in 14 (77.8%), 2 (11.1%) and 
2 (11.1%) (figure 3). Late mpMRI showed score 1 (highly unlikely), 2 (unlikely), 3 (equivocal), 4 (likely) 
and 5 (highly likely) in 7 (38.9%), 6 (33.3%), 3 (16.7%), 1 (5.6%) and 1 (5.6%) patients. The two 
patients with score 4-5 had no radiological evidence of in-field residual disease (i.e., in the treated 
area), but presented with radiological progression of known out-of-field (i.e., non-treated tissue); 
both underwent focal-HIFU. No other patient underwent another form of focal or radical treatment; 
none died or developed distant disease. 
 
 
 
 
4. Discussion 
In summary, our study shows that MRI-TRUS fusion focal cryotherapy is feasible in most patients 
choosing to have focal cryotherapy, has low toxicity and low impact on genito-urinary function with 
encouraging early ablation based on post-treatment MRI. 
Prior to discuss the implications of our study, we would like to acknowledge its limitations. First, the 
sample size is small although intentionally so due to the pilot nature of our study. Whilst selection 
bias is likely to be present and only well characterised men were included, we did not apply restrictive 
criteria. Only men scheduled for focal cryotherapy with visible disease were offered the procedure 
under MRI-TRUS fusion. This reflects real practice, and therefore should enhance external validity. 
Second, the study population was heterogeneous with most patients having primary disease but a 
number following other treatment failures. In this early stage of assessment, we did not aim to focus 
on a specific sub-group of men, but to explore the applicability of this procedure to the whole 
spectrum of men undergoing focal cryotherapy. Third, the lack of mandatory biopsy after treatment 
represents a limitation in the measurement of ablative effect, and we cannot derive robust oncological 
outcomes of this procedure based on this study. However, this was beyond the purpose of this early 
study. 
We assessed the feasibility of an established ablative source of energy combined with MRI-TRUS 
fusion to deliver focal therapy in a more precise fashion. Cryotherapy effect in ablating prostate 
cancer areas has been well proven, with a number of studies showing good efficacy, both when 
delivered as a whole-gland or a focal treatment [15, 16]. One randomised controlled trial has shown 
that cryotherapy might also have better disease control than radiation therapy [17]; a match-paired 
controlled study showed similar local control between focal cryotherapy and surgery [18]. Therefore, 
cryotherapy can provide reliable tissue effects, which in turn can be employed to assess the utility of 
novel technologies to guide focal therapy. 
The use of MRI-TRUS fusion to guide focal cryotherapy merits further reflection. The procedure was 
feasible in most cases, but as previously discussed, men presenting with recurrent disease might 
have tissue changes that can alter the imaging signal and cause distortion of the gland making rigid 
fusion difficult. Although we did not collect time spent for registration, in our experience, around 
additional 10 minutes were needed for mpMRI interpretation and contouring before treatment, and 
approximately 2 to 5 minutes for intraoperative imaging alignment. It should be noted that the 
operators were experts in mpMRI reading and Biojet software in light of previous experience in the 
biopsy setting [12]. We felt the fusion was straight-forward and we did not encounter significant 
problems during the delivery of cryotherapy. In our experience, the use of MR/TRUS fusion was 
beneficial in determining the margins of treatment. This was true in all 3D-orientation as with the 
formation of the ice-ball the limits of the gland become poorly defined. For instance, for an anterior 
lesion like the one seen in figure 2, heterogeneity in the posterior extension with the basal extremity 
extending further towards the peripheral area, real-time visualization during ablation permitted us to 
set a predictable margin of treatment. 
Although we demonstrated feasibility of guiding focal ablation and pilot data for a low rate of 
adverse events and good functional outcomes, without direct comparison against standard focal 
cryotherapy, we cannot determine the true utility of employing of a MRI-TRUS fusion device for 
treatment planning. In this stage I-IIa prospective development study adherent to the IDEAL 
guidelines, we focused on feasibility, technical success and assessment of toxicity using validated 
tools. The next stage of assessment might be a multi-centre study with careful assessment of medium 
term results using biopsy as the outcome of success, or a comparative study against focal cryotherapy 
without no use of software. 
 
 
 
 
5. Conclusion 
 
 
In conclusion, this study shows that MRI-TRUS fusion focal cryotherapy is feasible in most patients 
and seems to accurately guide ablation demonstrated by post-treatment imaging. Additional studies 
are needed to determine efficacy using post-cryotherapy biopsy. 
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Legends 
 
 
 
 
 
Figure 1 
 
 
Preoperative multiparametric MRI  showing a 4/5 score right anterior  lesion (red arrow) slightly 
crossing the midline on the left with low T2 signal, marked restricted diffusion and mild 
enhancement (figure 1). A small equivocal lesion scoring 3/5 was also seen in the posterolateral left 
apex. This patient underwent template prostate mapping  biopsies confirming  the right anterior lesion 
harbouring Gleason 3+4, maximum cancer core length 10mm. Biopsy in the rest of the gland showed 
no disease. This patient underwent MR/TRUS focal cryotherapy. 
 
 
 
 
Figure 2 
 
 
Step-by-step description of the utility of MR/TRUS fusion in focal cryotherapy. First, MR to TRUS 
fusion is performed at the beginning of the procedure. The needles are then placed under MR/TRUS 
fusion. Note that in this case the bottom cryotherapy needle was placed into the margin of the 
tumour (middle image). As the ablation area expands around, a 1cm margin is secured. Finally, real- 
time control of the ice-ball is possible also without fusion, but the continuous presence of the MR 
contour over the ultrasound allows to verify lesion coverage as well as adequate margins. 
 
 
 
 
Figure 3 
 
 
One week contrast enhanced MRI showing complete ablation in the treatment area (blue arrow). 
Follow mpMRI at 12 months shows right anterior gland distortion on T2 anatomical sequences with 
no residual restriction on DWI, and absence of suspicious enhancement on DCE (green arrow). 
 
 
 
 
Supplementary figure 1 
 
 
Box and whisker graph displaying sexual function variation after treatment, as measured by the IIEF- 
15 questionnaire. 
 
 
 
 
Supplementary figure 2 
Box and whisker graph displaying urinary function variation after treatment, as measured by the IPSS 
questionnaire. 
 
 
 
 
Supplementary figure 3 
 
 
Box and whisker graph displaying the variation of IPSS quality of life domain after treatment. 
 
 
 
 
 
Supplementary figure 4 
 
 
Box and whisker graph displaying continence function variation after treatment, as measured by the 
UCLA-EPIC incontinence questionnaire. 
 
 
 
 
Supplementary figure 5 
 
 
Box and whisker graph displaying the variation of PSA value after treatment. 
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